Table 2.

Treatment Characteristics.

	All Patients	HDR-BT Upfront	IMRT Upfront	p-value*
	(n = 115)	(n = 58)	(n = 57)
Treatment Year
2014	6 (5.2%)	6 (10.3%)	0 (0%)
2015	22 (19.1%)	20 (34.5%)	2 (3.5%)
2016	19 (16.5%)	12 (20.7%)	7 (12.3%)	<0.001
2017	22 (19.1%)	4 (6.9%)	18 (31.6%)
2018	20 (17.4%)	4 (6.9%)	16 (28.1%)
2019	26 (22.1%)	12 (20.7%)	14 (24.6%)
Interval between HDR-BT and IMRT (days)
Median (range)	20 (3–108)	21 (10–38)	19 (3–108)	NS
Androgen-deprivation therapy (ADT)	110 (95.6%)	53 (91.4%)	56 (98.2%)	NS
Duration of ADT (months)
Median (range)	12 (0–32)	18 (0–30)	7 (0–32)	NS
IMRT
Prostate/Seminal Vesicle	26 (22.6%)	15 (25.9%)	11 (19.3%)	NS
Whole Pelvis	89 (77.4%)	43 (74.1%)	46 (80.7%)	NS
Prostate volume at volume study
Median (range)	26.5 (9.4 – 84.9)	26.2 (9.4–58.8)	27.5 (12.3 – 84.9)	NS
	2 (1.7%)	0 (0%)	2 (3.5%)	NS
> 60 cc
Prostate volume at brachytherapy
Median (range)	28.1 (12.6–82.8)	28.0 (12.6 – 67.2)	29.3 (13.8 – 82.8)	NS
>60 cc	6 (5.2%)	2 (3.4%)	4 (7.0%)	NS
Bladder Perforated	24 (20.9%)	12 (20.7%)	12 (21.1%)	NS
Urethra Perforated	3 (2.6%)	1 (1.7%)	2 (3.5%)	NS
Number of needles implanted
Median (range)	16 (13–20)	16 (13–19)	16 (14–20)	NS
Prostate PTV V100 (%)
Mean (SD)	95.93 ± 2.28	95.4 ± 2.7	96.4 ± 1.6	NS
Bladder V75 (%)
Mean (SD)	0.2 ± 0.3	0.2 ± 0.3	0.2 ± 0.2	NS
Rectum V75 (%)
Mean (SD)	0.4 ± 0.3	0.4 ± 0.3	0.3 ± 0.3	NS
Urethra V125 (%)
Mean (SD)	0.1 ± 0.2	0.1 ± 0.2	0.1 ± 0.2	NS

Abbreviations: HDR, high dose rate; BT, brachytherapy; IMRT, intensity modulated radiation therapy; ADT, androgen deprivation therapy; PTV, planning target volume; V100, % volume of organ receiving ≥100% prescription dose; V75, % volume of organ receiving ≥75% prescription dose; V125, % volume of organ receiving 125% prescription dose; SD, standard deviation; NS = not significant.

*Pearson and Wilcoxon statistical tests employed to compare cohorts.